Insight, China's Pharmaceutical Industry

Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Santo Therapeutics, a Hangzhou-based in vivo gene therapy developer, announced it has received both Orphan...

Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Fineline Cube Apr 28, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced that its supplemental Biologics License Application (sBLA) for...

Company Drug

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

Fineline Cube Apr 28, 2026

AbbVie (NYSE: ABBV) announced it has submitted a marketing approval filing to the U.S. Food...

Company Drug

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

Fineline Cube Apr 28, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) announced on April 27, 2026, that efimosfermin, a once-monthly investigational...

Company Drug

Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline

Fineline Cube Apr 28, 2026

Prothena Corporation plc (NASDAQ: PRTA) announced that the U.S. Food and Drug Administration (FDA) has...

Company Drug

Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors – Novel Bispecific Fc Fusion Protein Targets “Cold Tumors”

Fineline Cube Apr 28, 2026

Jecho Biopharmaceuticals Co., Ltd., a China-based joint venture between U.S.-based Jecho Laboratories, Inc. and France-headquartered...

Others

Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication

Fineline Cube Apr 28, 2026

Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced this week that Botox has received marketing...

Others

Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A

Fineline Cube Apr 28, 2026

Huahui Health, a Beijing-based biotechnology company focused on viral hepatitis, hepatology, and oncology, announced a...

Company

WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion

Fineline Cube Apr 28, 2026

WuXi AppTec Co., Ltd. (SHA: 603259; HKG: 2359), China’s leading integrated Contract Research Organization (CRO),...

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026

Thermo Fisher Scientific Inc. (NYSE: TMO) announced on April 27, 2026, that it has signed...

Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Fineline Cube Apr 28, 2026

Novartis AG (NYSE: NVS) announced on April 27, 2026, that the European Commission (EC) has...

Others

Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms

Fineline Cube Apr 28, 2026

Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. announced a definitive agreement on...

Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026

Aureka Biotechnologies, a global leader in the Tech-Bio space, announced the completion of its Series...

Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026

Guangzhou BeBetter Medicine Technology Co., Ltd. (SHA: 688759) announced it has received approval from the...

Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China

Fineline Cube Apr 28, 2026

Hinova Pharmaceuticals Inc. (SHA: 688302) announced positive interim results from its Phase IIa clinical study...

Others

Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry

Fineline Cube Apr 28, 2026

Bio-Thera Solutions Ltd. (SHA: 688177) announced its financial results for fiscal year 2025, reporting revenues...

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026

Adcoris, a Hangzhou-based bioconjugation specialist, announced a global licensing agreement with U.S.-headquartered K2 Therapeutics, Inc....

Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026

Chia Tai Tianqing Pharmaceutical Group, a wholly owned subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177),...

Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Fineline Cube Apr 27, 2026

Novartis AG (NYSE: NVS) announced that the Committee for Medicinal Products for Human Use (CHMP)...

Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Fineline Cube Apr 27, 2026

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the Center for Drug Evaluation (CDE)...

Insight, China's Pharmaceutical Industry

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline

Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors – Novel Bispecific Fc Fusion Protein Targets “Cold Tumors”

Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication

Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A

WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China

Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

You Missed

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development